Vaccinia virus-based vector against infectious diseases and tumors

References

• Liu MA. Vaccine developments. Nat Med. 1998;4:515–19. doi:10.1038/nm0598supp-515.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–62. doi:10.1038/nrd4663.
   PubMed Web of Science ®Google Scholar
• Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba N, Halwe S, Rohde C, Eickmann M, Volz A, et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis. 2020;20:827–38. doi:10.1016/S1473-3099(20)30248-6.
   PubMed Web of Science ®Google Scholar
• Potts KG, Irwin CR, Favis NA, Pink DB, Vincent KM, Lewis JD, Moore RB, Hitt MM, Evans DH. Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models. EMBO Mol Med. 2017;9:638–54. doi:10.15252/emmm.201607296.
   PubMed Web of Science ®Google Scholar
• Scutts SR, Ember SW, Ren H, Ye C, Lovejoy CA, Mazzon M, Veyer DL, Sumner RP, Smith GL. DNA-PK is targeted by multiple vaccinia virus proteins to inhibit DNA sensing. Cell Rep. 2018;25:1953–65. doi:10.1016/j.celrep.2018.10.034.
   PubMed Web of Science ®Google Scholar
• Kleinpeter P, Remy-Ziller C, Winter E, Gantzer M, Nourtier V, Kempf J, Hortelano J, Schmitt D, Schultz H, Geist M, et al. By binding CD80 and CD86, the vaccinia virus M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80 Binding to PD-L1. J Virol. 2019;93. doi:10.1128/JVI.00207-19.
   Web of Science ®Google Scholar
• Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 1982;79:7415–19. doi:10.1073/pnas.79.23.7415.
   PubMed Web of Science ®Google Scholar
• Kennedy RB, Ovsyannikova I, Poland GA. Smallpox vaccines for biodefense. Vaccine. 2009;27(Suppl 4):D73–D79. doi:10.1016/j.vaccine.2009.07.103.
   PubMed Web of Science ®Google Scholar
• Garcia-Arriaza J, Esteban M. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother. 2014;10:2235–44. doi:10.4161/hv.28974.
   PubMed Web of Science ®Google Scholar
• Nakatake M, Kurosaki H, Kuwano N, Horita K, Ito M, Kono H, Okamura T, Hasegawa K, Yasutomi Y, Nakamura T. Partial deletion of glycoprotein B5R enhances vaccinia virus neutralization escape while preserving oncolytic function. Mol Ther Oncolytics. 2019;14:159–71. doi:10.1016/j.omto.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019;11. doi:10.1126/scitranslmed.aax1880.
   Web of Science ®Google Scholar
• Colby DJ, Sarnecki M, Barouch DH, Tipsuk S, Stieh DJ, Kroon E, Schuetz A, Intasan J, Sacdalan C, Pinyakorn S, et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat Med. 2020;26:498–501. doi:10.1038/s41591-020-0774-y.
   PubMed Web of Science ®Google Scholar
• Mega ER. ‘Mosaic’ HIV vaccine to be tested in thousands of people across the world. Nature. 2019;572:165–66. doi:10.1038/d41586-019-02319-8.
   PubMed Web of Science ®Google Scholar
• Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science. 2012;336:1534–41. doi:10.1126/science.1213362.
   PubMed Web of Science ®Google Scholar
• Fouchier RA, Garcia-Sastre A, Kawaoka Y. H5N1 virus: transmission studies resume for avian flu. Nature. 2013;493:609. doi:10.1038/nature11858.
   PubMed Web of Science ®Google Scholar
• Xie X, Zhao C, He Q, Qiu T, Yuan S, Ding L, Liu L, Jiang L, Wang J, Zhang L, et al. Influenza vaccine with consensus internal antigens as immunogens provides cross-group protection against influenza A viruses. Front Microbiol. 2019;10:1630. doi:10.3389/fmicb.2019.01630.
   PubMed Web of Science ®Google Scholar
• Perez P, Lazaro-Frias A, Jimenez DON, Blazquez AB, Escribano-Romero E, Ortego J, Saiz JC, Esteban M, et al. A vaccine based on a modified vaccinia virus ankara vector expressing zika virus structural proteins controls zika virus replication in mice. Sci Rep. 2018;8:17385. doi:10.1038/s41598-018-35724-6.
   PubMed Web of Science ®Google Scholar
• Deng Y, Chuai X, Chen P, Chen H, Wang W, Ruan L, Li W, Tan W. Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques. Vaccine. 2017;35:3347–53. doi:10.1016/j.vaccine.2017.04.059.
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329–36. doi:10.1038/nm.3089.
   PubMed Web of Science ®Google Scholar
• Deng L, Fan J, Guo M, Huang B. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9. Cancer Lett. 2016;372:251–57. doi:10.1016/j.canlet.2016.01.025.
   PubMed Web of Science ®Google Scholar
• Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O’Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther. 2016;24:1492–501. doi:10.1038/mt.2016.101.
   PubMed Web of Science ®Google Scholar
• McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751–57.
   PubMed Web of Science ®Google Scholar
• Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther. 2015;23:202–14. doi:10.1038/mt.2014.194.
   PubMed Web of Science ®Google Scholar
• Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 2002;9:1022–35. doi:10.1038/sj.cgt.7700542.
   PubMed Web of Science ®Google Scholar
• Deng L, Yang X, Fan J, Ding Y, Peng Y, Xu D, Huang B, Hu Z. An oncolytic vaccinia virus armed with GM-CSF and IL-24 double genes for cancer targeted therapy. Onco Targets Ther. 2020;13:3535–44. doi:10.2147/OTT.S249816.
   PubMed Web of Science ®Google Scholar
• Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:432518737. doi:10.1177/1758835919833519.
   Web of Science ®Google Scholar
• Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer Immunol Immunother. 2014;63:161–74. doi:10.1007/s00262-013-1494-7.
   PubMed Web of Science ®Google Scholar
• Berkeley RA, Steele LP, Mulder AA, van den Wollenberg D, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, et al. Antibody-neutralized reovirus is effective in oncolytic virotherapy. Cancer Immunol Res. 2018;6:1161–73. doi:10.1158/2326-6066.CIR-18-0309.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka R, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018;174:1031–32. doi:10.1016/j.cell.2018.07.035.
   PubMed Web of Science ®Google Scholar
• Yang R, Wang L, Sheng J, Huang Q, Pan D, Xu Y, Yan J, Wang X, Dong Z, Yang M. Combinatory effects of vaccinia virus VG9 and the STAT3 inhibitor Stattic on cancer therapy. Arch Virol. 2019;164:1805–14. doi:10.1007/s00705-019-04257-2.
   PubMed Web of Science ®Google Scholar